I got my ARB losses back. @dom_dillionz @praween_nusrat @IsmayaRania @KeerthiGeeth @seriouscawcaw @SadracChora @mazharkazmi123 @Blessroth
English
Swetha Kambhampati
285 posts
Swetha Kambhampati
@SwethaKMD
Assistant Professor at City of Hope; Alum: UCSF heme/onc, Hopkins IM, Stanford Med; Interested in lymphoma and CART
Los Angeles, CA Katılım Şubat 2010
274 Takip Edilen478 Takipçiler
Im SHIB for always @nunez_julian @hex_xyiv @karshaleos @Crofwgkta @rost_1989 @diazruben16sj @MUSICSAOLOR @vinccirom
English
SHIB for life @KazeemKhaled @186 @ZakaCrypto @devanpr03 @JosephDShook @Div_R2022 @an49787142 @SuyatnoJayadin2 @unyil0109
English
Chilling with my ARB reimbursement money @Irmatralala_ @Abdulaz84267922 @michael27677957 @MindySpurlock1 @T1_034 @Nino369Nino369 @HoaTrongTuyt1 @Moneymagnet84
English
Im SHIB for always @Nidhi90868859 @allwar71 @Emerald09918692 @LLove6688 @mimi_VOD @AxSidh @pjmlantunes @TheFreedomProt1
English
I just went into beta its so FIRE @GLC_Inc_ @SamuelP40277471 @ConnieG168 @ClemonTinnel @Hutchin95272841 @SosoMauro @kisaan5556678 @0xmengzi
English
When's public ARB @maron_MaHaLo @EvanANorman @Homelander144 @ThnhNgu02050662 @dung_nhan_vao @nachampn @elekxmiki @minisatthu @kinobe_ @Kriptoagatmi
English
Swetha Kambhampati retweetledi
Developing the treatments of tomorrow is hard work. @DoctorAKrishnan, M.D., and @elizabeth_budde, M.D., Ph.D., are leading a few clinical trials related to bispecific antibodies and their ability to target cancer cells more precisely than chemo. bit.ly/3LTlAoi #HemOnc
English
Swetha Kambhampati retweetledi
Axicabtagene ciloleucel showed a significant improvement in OS over standard of care in patients with relapsed or refractory LBCL, according to the primary OS analysis of the phase III ZUMA-7 study released by @KitePharma.
bloodcancerstoday.com/post/zuma-7-su…
English
Swetha Kambhampati retweetledi
🔊OUT NOW: This all-new episode of The HemOnc Pulse features host @chadinabhan speaking with @SwethaKMD of @cityofhope and Nikhil Thiruvengadam, MD, about the cost effectiveness of pola-R-CHP in relation to other therapies for DLBCL.
@SocietyofHemOnc
bloodcancerstoday.com/podcast/what-i…
English
I got my Shib Yards @OlegDCH @Iura57163635 @CherkutP @HuongNt40173119 @Dim4err_ @413647746Peter @mohammedhafida1 @NdkhoaE
English
Swetha Kambhampati retweetledi
Huge news! ZUMA-7 trial shows axi-cel improves overall survival in patients with second-line aggressive lymphoma, compared to chemo/autoSCT. Statistically significant, which should end the “try chemo first” argument. Full data to be presented in the next few months. #lymsm
Kite, a Gilead Company@KitePharma
#NEWS: Today, we announced the primary overall survival (OS) analysis results, a key secondary endpoint, of our Phase 3 study of CAR T-cell therapy for initial treatment of relapsed/refractory large B-cell lymphoma.
English
Dr. Ayushi Chauhan @Chauhan_AF from @GACancerCenter named the 2023 Stephanie A. Gregory Distinguished Scholar by the Lymphoma Research Foundation @lymphoma. A brilliant young investigator. Very proud of her accomplishments.
English
English
Congratulations @SwethaKMD and Nikhil. A true power couple! @WomenInLymphoma
Blood Cancers Today@Blood_Cancers
🔊Coming Thursday, 3/23: An all-new episode of The HemOnc Pulse features host @chadinabhan speaking with @SwethaKMD of @cityofhope and Nikhil Thiruvengadam, MD, of @UCSF about modeling the cost effectiveness of pola-R-CHP in relation to other DLBCL therapies. @SocietyofHemOnc
English
Congrats @SwethaKMD!!!
Blood Cancers Today@Blood_Cancers
🔊Coming Thursday, 3/23: An all-new episode of The HemOnc Pulse features host @chadinabhan speaking with @SwethaKMD of @cityofhope and Nikhil Thiruvengadam, MD, of @UCSF about modeling the cost effectiveness of pola-R-CHP in relation to other DLBCL therapies. @SocietyofHemOnc
Seattle, WA 🇺🇸 English
Swetha Kambhampati retweetledi
🔊Coming Thursday, 3/23: An all-new episode of The HemOnc Pulse features host @chadinabhan speaking with @SwethaKMD of @cityofhope and Nikhil Thiruvengadam, MD, of @UCSF about modeling the cost effectiveness of pola-R-CHP in relation to other DLBCL therapies.
@SocietyofHemOnc
English
Swetha Kambhampati retweetledi
Excited the City of Hope experience with bridging therapy prior to CAR T for LBCL is published. Thanks for the collaboration between @COH_RadOnc and @COHMedOnc. Stay tuned for our prospective trial shortly! mdpi.com/2072-6694/15/6…
English
Phenomenal and inspirational week at LRF LSRMP! great mentorship and developed life long friendships and connections! Grateful for the experience @lymphoma @cityofhope
Timothy Voorhees, MD, MSCR@tvoorheesmd
Amazing week with LRF LSRMP at Lake Las Vegas. Great protocol development. Meeting mentors and colleagues was invaluable! @lymphoma @OSUHematology
English